Trial Profile
EFC6596 (CINJ 070703): A Randomized, Open Label Multi-Center Study Of Single Agent Larotaxel (XRP9881) Compared To Continuous Administration of 5-FU For The Treatment Of Patients With Advanced Pancreatic Cancer Previously Treated With A Gemcitabine-Containing Regimen.
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 05 Oct 2021
Price :
$35
*
At a glance
- Drugs Larotaxel (Primary) ; Capecitabine; Fluorouracil
- Indications Adenocarcinoma; Pancreatic cancer
- Focus Registrational; Therapeutic Use
- Acronyms PAPRIKA
- Sponsors Sanofi
- 30 Jun 2010 Actual patient number added.
- 30 Jun 2010 Results were presented at the 12th World Congress on Gastrointestinal Cancer (2010).
- 29 Dec 2009 Actual end date (Nov 2009) added as reported by ClinicalTrials.gov.